General Use Epinephrine Program

Key Updates to the 2017-2018 Program



Archdiocese of Baltimore

Department of Catholic Schools

Office of Risk Management

2017/2018 School Year

**2017-2018 Archdiocese of Baltimore**

**General Use Epinephrine Policy and Procedure Updates**

1. There are no updates to the General Use Epinephrine Program policy and procedure documents as issued by the Office of Risk management.
2. In October 2015, Sanofi US voluntarily recalled all **Auvi‑Q**(epinephrine injection, USP). **The recall involved all Auvi‑Q currently on the market** and includes both the

0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers. This included lot numbers 2081278 through 3037230, which expire October 2015 through December 2016.

1. The resources have been updated.
2. The American Academy and NASN recommend changing the weight/height guidelines for determination of dose from 66lbs/ 135cm to 55lbs/ 125cm. Please see the referenced presentation for more information on food allergy management: <https://www.aap.org/en-us/Documents/practicesupport_food_allergy_epidemiology_diagnosis_management_presentation_slides.pdf> (to get the PDF to work please copy and paste this URL into your internet browser).

FDA guidelines and auto-injectable epinephrine packaging still use the 66lbs/135cm guidelines for the determination of dose. Therefore the Archdiocese General Use Policy and Procedure for 2016-2017 still reflects the 66lbs/135 cm guidelines. Your school’s physician/licensed prescriber should review the above presentation and make a determination as to which guidelines to be used.

1. Please review this article on adolescents and food allergy management: <http://allergicliving.com/2015/10/20/teens-speak-up-about-averting-food-allergy-tragedies/1/>